Literature DB >> 12063673

Tumor markers as clinical cancer tests--are we there yet?

Richard L Schilsky1, Sheila E Taube.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12063673     DOI： 10.1053/sonc.2002.32890

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  10 in total

Review 1.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.

Authors:  Giuseppe Sconocchia; Inti Zlobec; Alessandro Lugli; Diego Calabrese; Giandomenica Iezzi; Eva Karamitopoulou; Efstratios S Patsouris; George Peros; Milo Horcic; Luigi Tornillo; Markus Zuber; Raoul Droeser; Manuele G Muraro; Chantal Mengus; Daniel Oertli; Soldano Ferrone; Luigi Terracciano; Giulio C Spagnoli
Journal:  Int J Cancer       Date:  2010-10-13       Impact factor: 7.396

4.  Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml.

Authors:  Hyoung Woo Kim; Young Hwii Ko; Seok Ho Kang; Jeong Gu Lee
Journal:  Korean J Urol       Date:  2011-03-18

Review 5.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

6.  PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

Authors:  A-Jian Li; Hua-Guang Li; Er-Jiang Tang; Wei Wu; Ying Chen; Hui-Hong Jiang; Mou-Bin Lin; Lu Yin
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

7.  Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors.

Authors:  Shiva Shrotriya; Declan Walsh; Amy S Nowacki; Cliona Lorton; Aynur Aktas; Barbara Hullihen; Nabila Benanni-Baiti; Katherine Hauser; Serkan Ayvaz; Bassam Estfan
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

8.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

9.  Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen.

Authors:  Young Min Kim; Sungchan Park; June Kim; Seonghun Park; Ji Ho Lee; Dong Soo Ryu; Seong Hoon Choi; Sang Hyeon Cheon
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

10.  A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men.

Authors:  Nigel P Murray; Eduardo Reyes; Nelson Orellana; Cynthia Fuentealba; Ricardo Dueñas
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.